Myricitrin – a flavonoid isolated from the Indian olive tree (<i>Elaeocarpus floribundus</i>) – inhibits Monoamine oxidase in the brain and elevates striatal dopamine levels: therapeutic implications against Parkinson's disease

Banerjee, Chayan; Nandy, Sumangal; Chakraborty, J.; Kumar, Deepak

doi:10.1039/d2fo00734g

Cited by 16 publications

(9 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Research has emphasized myricetin, a flavonoid that has shown inhibitory effects on MAO, indicating its ability to decrease MAO levels. 50 Apigenin, isoquercetrin, and quercetrin are well-recognized flavonoids that have shown neuroprotective and anti-inflammatory properties. 51 These flavonoids have the potential to increase the capacity of the extract to regulate MAO concentrations.…”

Section: Discussionmentioning

confidence: 99%

Exploring beetroot (Beta vulgaris L.) for diabetes mellitus and Alzheimer's disease dual therapy: in vitro and computational studies

Ojo,

Gyebi,

Ezenabor

et al. 2024

RSC Adv.

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Exploring beetroot (Beta vulgaris L.) for diabetes mellitus and Alzheimer's disease dual therapy: in vitro and computational studies

Ojo,

Gyebi,

Ezenabor

et al. 2024

RSC Adv.

View full text Add to dashboard Cite

show abstract

“…Striatal tissue is prepared for DA level measurement following the protocol stated as earlier [ 84 ]. Sample is injected into a HPLC system (Thermo ultimate 3000) through a Rheodyne injector, equipped with a glassy carbon electrochemical detector.…”

Section: Methodsmentioning

confidence: 99%

Calcineurin inhibition protects against dopamine toxicity and attenuates behavioral decline in a Parkinson’s disease model

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background Parkinson’s disease (PD), a highly prevalent neuro-motor disorder is caused due to progressive loss of dopaminergic (DAergic) neurons at substantia nigra region of brain. This leads to depleted dopamine (DA) content at striatum, thus affecting the fine tuning of basal ganglia. In patients, this imbalance is manifested by akinesia, catalepsy and tremor. PD associated behavioral dysfunctions are frequently mitigated by l-DOPA (LD) therapy, a precursor for DA synthesis. Due to progressive neurodegeneration, LD eventually loses applicability in PD. Although DA is cytotoxic, it is unclear whether LD therapy can accelerate PD progression or not. LD itself does not lead to neurodegeneration in vivo, but previous reports demonstrate that LD treatment mediated excess DA can potentiate neurotoxicity when PD associated genetic or epigenetic aberrations are involved. So, minimizing DA toxicity during the therapy is an absolute necessity to halt or slowdown PD progression. The two major contributing factors associated with DA toxicity are: degradation by Monoamine oxidase and DAquinone (DAQ) formation. Results Here, we report that apoptotic mitochondrial fragmentation via Calcineurin (CaN)-DRP1 axis is a common downstream event for both these initial cues, inhibiting which can protect cells from DA toxicity comprehensively. No protective effect is observed, in terms of cell survival when only PxIxIT domain of CaN is obstructed, demonstrating the importance to block DRP1-CaN axis specifically. Further, evaluation of the impact of DA exposure on PD progression in a mice model reveal that LD mediated behavioral recovery diminishes with time, mostly because of continued DAergic cell death and dendritic spine loss at striatum. CaN inhibition, alone or in combination with LD, offer long term behavioral protection. This protective effect is mediated specifically by hindering CaN-DRP1 axis, whereas inhibiting interaction between CaN and other substrates, including proteins involved in neuro-inflammation, remained ineffective when LD is co-administered. Conclusions In this study, we conclude that DA toxicity can be circumvented by CaN inhibition and it can mitigate PD related behavioral aberrations by protecting neuronal architecture at striatum. We propose that CaN inhibitors might extend the therapeutic efficacy of LD treatment.

show abstract

“…Myricitrin’s therapeutic potential was examined in a mouse brain model by Banerjee et al In the mouse brain, myricitrin reduced MAO activity and increased DA levels. In the PD mouse model, myricitrin could lessen motor incoordination and elevate the DA levels in the striatum ( Banerjee et al, 2022 ).…”

Section: Phytoconstituents In Different Neurological Disordersmentioning

confidence: 99%

Natural product-based pharmacological studies for neurological disorders

Puri

Kanojia²,

Sharma³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Central nervous system (CNS) disorders and diseases are expected to rise sharply in the coming years, partly because of the world’s aging population. Medicines for the treatment of the CNS have not been successfully made. Inadequate knowledge about the brain, pharmacokinetic and dynamic errors in preclinical studies, challenges with clinical trial design, complexity and variety of human brain illnesses, and variations in species are some potential scenarios. Neurodegenerative diseases (NDDs) are multifaceted and lack identifiable etiological components, and the drugs developed to treat them did not meet the requirements of those who anticipated treatments. Therefore, there is a great demand for safe and effective natural therapeutic adjuvants. For the treatment of NDDs and other memory-related problems, many herbal and natural items have been used in the Ayurvedic medical system. Anxiety, depression, Parkinson’s, and Alzheimer’s diseases (AD), as well as a plethora of other neuropsychiatric disorders, may benefit from the use of plant and food-derived chemicals that have antidepressant or antiepileptic properties. We have summarized the present level of knowledge about natural products based on topological evidence, bioinformatics analysis, and translational research in this review. We have also highlighted some clinical research or investigation that will help us select natural products for the treatment of neurological conditions. In the present review, we have explored the potential efficacy of phytoconstituents against neurological diseases. Various evidence-based studies and extensive recent investigations have been included, which will help pharmacologists reduce the progression of neuronal disease.

show abstract

Myricitrin – a flavonoid isolated from the Indian olive tree (Elaeocarpus floribundus) – inhibits Monoamine oxidase in the brain and elevates striatal dopamine levels: therapeutic implications against Parkinson's disease

Abstract: Flavonoids exhibit several biological activities including Monoamine oxidase (MAO) inhibition, an enzyme that metabolizes several neurotransmitters. Thus, MAO inhibitors are well included in traditional therapeutic practices to fine-tune neuromotor behavior....

Cited by 16 publications

References 54 publications

Exploring beetroot (Beta vulgaris L.) for diabetes mellitus and Alzheimer's disease dual therapy: in vitro and computational studies

Exploring beetroot (Beta vulgaris L.) for diabetes mellitus and Alzheimer's disease dual therapy: in vitro and computational studies

Calcineurin inhibition protects against dopamine toxicity and attenuates behavioral decline in a Parkinson’s disease model

Natural product-based pharmacological studies for neurological disorders

Contact Info

Product

Resources

About